Chest
-
Lung Cancer Posters ISESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Bronchopulmonary (BP) carcinoids are rare neuroendocrine tumors comprising of 1.1 % of all pulmonary cancers. To our knowledge no single study had been done using large cancer database evaluating bronchopulmonary carcinoids in particular with respect to their anatomical distribution and the impact of staging, histological grade, treatment offered and racial distribution on five year relative survival rates. ⋯ The following authors have nothing to disclose: Hari Prasad Ravipati, Srinadh Annangi, Swathi Nutakki, Christine Charaf, Eric FlenaughNo Product/Research Disclosure Information.
-
Multicenter Study
Predicting Pulmonary Fibrosis Disease Course from Past Trends in Pulmonary Function.
The clinical course of idiopathic pulmonary fibrosis (IPF) is characterized by progressive decline in lung function and eventual mortality. We sought to determine if future declines in pulmonary function, mortality, or both can be predicted from prior trends in pulmonary function tests (PFTs). ⋯ PFT decline predicts early mortality, but not future declines in physiology, regardless of time since diagnosis.
-
COPD QVA149 PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: QVA149 is a once-daily dual bronchodilator containing a fixed-dose combination of the long-acting β2-agonist (LABA) indacaterol and long-acting muscarinic antagonist (LAMA) glycopyrronium (NVA237), for the treatment of chronic obstructive pulmonary disease (COPD). The BEACON study evaluated the efficacy and safety of QVA149 compared with the concurrent administration of indacaterol and glycopyrronium (IND+GLY). ⋯ The study demonstrated that QVA149 provides benefits of dual bronchodilation in a single inhaler device, making it a more convenient treatment option for patients with moderate-to-severe COPDDISCLOSURE: Ronald Dahl: Consultant fee, speaker bureau, advisory committee, etc.: In the past 3 years, Professor Dahl has received compensation for consulting with Boehringer-Ingelheim, Novartis, Vectura, Roche, Elevation Pharma and Norpharma; has undertaken research funded by AstraZeneca, Boehringer- Ingelheim, C hiesi, GlaxoSmithKline, Novartis, ALK-Abello and Stallergenes; has participated in educational activities sponsored by AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, ALK-Abello, Novartis, Almirall. Dalal Jadayel: Employee: Novartis Employee Vijay Alagappan: Employee: Novartis Employee Hungta Chen: Employee: Novartis Employee Donald Banerji: Employee: Novartis EmployeeClinical trial results of QVA149, combination of two approved products indacaterol and glycopyrronium, will be presented, QVA149 is in the late stage phase 3 trials prior to approval.
-
COPD Comorbidity PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: The Baseline (BDI) and Transition Dyspnea Index (TDI) are interview-based multidimensional instruments to assess breathlessness in patients with COPD. However, BDI/TDI interviewer process may introduce bias in the interpretation, leading to more variability in results. Innovative self-administered computerized (SAC) versions of the BDI/TDI were developed and validated for the BLAZE study which allows patients to provide direct ratings of breathlessness based on activities of daily living. ⋯ Anthony D'Urzo: Consultant fee, speaker bureau, advisory committee, etc.: AD has received research, consulting and lecturing fees from GlaxoSmithkline, Sepracor, Schering Plough, Altana, Methapharma, AstraZeneca, ONO pharma, Merck Canada, Forest Laboratories, Novartis Canada/USA, Boehringer Ingelheim (Canada) Ltd, Pfizer Canada, SkyePharma, and KOS Pharmaceuticals. Donald Mahler: Consultant fee, speaker bureau, advisory committee, etc.: The presenting author is a consultant for GlaxoSmithKline, Novartis, and Sunovion, and have served on Advisory Boards for Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pearl, and Sunovion, The C linical Trials Office at Dartmouth-Hitchcock Medical C enter (DHMC ) is currently receiving grants for clinical trials from Boehringer Ingelheim, Novartis, and Sunovion; Donald A. Mahler, M.D. is the DHMC principal investigator for these studies. Tracy White: Employee: Novartis employee Vijay Alagappan: Employee: Novartis employee Hungta Chen: Employee: Novartis employee Karoly Kulich: Employee: Novartis employee Nicola Gallagher: Employee: Novartis employee Donald Banerji: Employee: Novartis employee The following authors have nothing to disclose: Vanessa BrunelClinical trial results of QVA149, combination of two approved products indacaterol and glycopyrronium, will be presented, QVA 149 is in the late stage phase 3 trials prior to approval.
-
Asthma PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Aspirin Exacerbated Respiratory Disease (AERD) is commonly associated with chronic rhinosinusitis with nasal polyps (CRSwNP). Few information is available on the correlation between aspirin sensitivity and severe asthma. The aim of this study was to investigate the association between aspirin sensitivity and severe asthma and the presence of CRSwNP in a cohort of asthmatic patients. ⋯ The following authors have nothing to disclose: Jose Castillo, Cesar Picado, Vicente Plaza, Gustavo Rodrigo, Berta Juliá, Joaquim MullolNo Product/Research Disclosure InformationClinicalTrials.gov ID: NCT01513837.